Cinclus Pharma: US phase 3 trial to start in Q3'25
Cinclus Pharma reported its Q4 results with a cash position at SEK566.7mm and an EBIT at SEK(56.89m). With the current cash position and operational cash burn, we forecast a runway into H1 2027 — i.e. beyond the next value inflection point of the phase 3 readout in Q3 2026. On the operational side,
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.